SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...
Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...
iRhythm Technologies recently launched its next-generation Zio monitor and enhanced Zio long-term continuous monitoring service in the United States. The San Francisco, CA-based company touts an ...
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac ...
Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio ® long-term ...
iRhythm’s first quarter results were well received by the market, driven by strong growth in its Zio product lines and expanding adoption among both traditional cardiology and new primary care ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback